Health Condition 1: null- Young Patients (less than 25 yrs of age) with history of dilated cardiomyopathy with onset less than 6 months before
Conditions
Interventions
Intervention1: Intravenous Immnunoglobulin (IVIG): IVIG in dose of 2g/kg over 3 days will be given to patient in intervention arm along with optimal medical therapy
Control Intervention1: Control Arm:
Sponsors
All india institute of medical sciences New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with dilated cardiomyopathy with LV dysfunction 2.History s/o viral illness or myocarditis in recent past 3.Patients with recent onset of symptoms with duration 4.Patients 5.Patients giving written informed consent
Exclusion criteria
Exclusion criteria: 1.Cardiomyopathy suspected to be from following etiologies: Familial Valvular heart disease Congenital heart disease HIV/HBV/HCV infection Secondary to bacterial infection elsewhere Arrhythmia Treatment with cardiotoxic agent in past 2.Patients >25 years of age 3.Inability to comply with the follow-up period 4.Patients not giving written consent for inclusion in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in LV End-diastolic dimension at 6 monthsTimepoint: at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To study event free survival i.e. death, hospitalization and transplant free survival at 6 monthsTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Sunilkumar Verma
AIIMS, New Delhi
Outcome results
None listed